Beishashen(BSS)and Maidong(MD)are commonly used Medicine right for the treatment of non-small cell lung cancer(NSCLC),but their specific mechanism of action is not clear.In this study,network pharmacology and molecula...Beishashen(BSS)and Maidong(MD)are commonly used Medicine right for the treatment of non-small cell lung cancer(NSCLC),but their specific mechanism of action is not clear.In this study,network pharmacology and molecular docking techniques were used to investigate the molecular mechanisms of the therapeutic effects of BSS-MD on NSCLC and to experimentally validate some of the targets.The network pharmacology approach,including active ingredient and target screening,drug-compound-target network construction,protein-protein interaction(PPI)network,enrichment analysis,and molecular docking,was used to investigate the mechanism of action of Beisashen and Maitong on NSCLC.First,the active components of BSS-MD and their targets were predicted,of which 423 targets interacted with NSCLC targets.Then,network pharmacology showed that Stigmasterol,Quercetin,Alloisoimperatorin,Isoimperatorin,Beta-sitosterol were the core components of BSS-MD,and PLK1,HSP90AB1,and CDK1 were the key therapeutic targets.KEGG enrichment analysis indicated that the mechanism of action of BSS-MD in NSCLC treatment was related to the cell cycle.Then we further performed experimental validation.CCK-8 assay showed that BSS-MD inhibited LEWIS cell viability and promoted apoptosis in a dose-dependent manner.qPCR assay,immunofluorescence,and protein blotting experiments demonstrated that compared with the control group and the control group,the expression of PLK1,HSP90AB1,and CDK1 mRNAs and proteins were reduced in the treatment group(P<0.01).Therefore,we conclude that BSS-MD can block cell cycle progression by inhibiting the expression of PLK1,CDK1,and HSP90AB1 mRNAs and proteins to inhibit lung cancer cell growth and promote apoptosis,and emphasize that BSS-MD are promising adjuvants for NSCLC treatment.展开更多
Objective: To evaluate the effect of Shashen Maidong Decoction (SSMDD) on gastric motility.Method: Effect of SSMDD on the gastric motility of mice and rats was observed in vivo by administration of SSMDD in various do...Objective: To evaluate the effect of Shashen Maidong Decoction (SSMDD) on gastric motility.Method: Effect of SSMDD on the gastric motility of mice and rats was observed in vivo by administration of SSMDD in various dosages and observation on gastric phenol red excretion rate, gastric emptying rate, frequency and amplitude of contraction of fundic longitudinal muscles, etc. Results: SSMDD could reduce markedly the gastric phenol red excretion rate of mice, antagonize the acceleration of gastric emptying induced by neostigmine, inhibit the frequency and amplitude of contraction of fundic longitudinal muscle, slow down the frequency and decrease the amplitude of gastric peristalsis, and reduce the gastric hypermotility induced by indomethacin significantly. Conclusion: SSMDD has evident inhibition action on motility of experimental animals in vivo, its mechanism might be related with adrenergic nerve and metabolism of prostaglandin E.展开更多
基金This research was supported by“Zhejiang Province Chinese Medicine Science and Technology Program Key Projects”(No.2021ZZ008).
文摘Beishashen(BSS)and Maidong(MD)are commonly used Medicine right for the treatment of non-small cell lung cancer(NSCLC),but their specific mechanism of action is not clear.In this study,network pharmacology and molecular docking techniques were used to investigate the molecular mechanisms of the therapeutic effects of BSS-MD on NSCLC and to experimentally validate some of the targets.The network pharmacology approach,including active ingredient and target screening,drug-compound-target network construction,protein-protein interaction(PPI)network,enrichment analysis,and molecular docking,was used to investigate the mechanism of action of Beisashen and Maitong on NSCLC.First,the active components of BSS-MD and their targets were predicted,of which 423 targets interacted with NSCLC targets.Then,network pharmacology showed that Stigmasterol,Quercetin,Alloisoimperatorin,Isoimperatorin,Beta-sitosterol were the core components of BSS-MD,and PLK1,HSP90AB1,and CDK1 were the key therapeutic targets.KEGG enrichment analysis indicated that the mechanism of action of BSS-MD in NSCLC treatment was related to the cell cycle.Then we further performed experimental validation.CCK-8 assay showed that BSS-MD inhibited LEWIS cell viability and promoted apoptosis in a dose-dependent manner.qPCR assay,immunofluorescence,and protein blotting experiments demonstrated that compared with the control group and the control group,the expression of PLK1,HSP90AB1,and CDK1 mRNAs and proteins were reduced in the treatment group(P<0.01).Therefore,we conclude that BSS-MD can block cell cycle progression by inhibiting the expression of PLK1,CDK1,and HSP90AB1 mRNAs and proteins to inhibit lung cancer cell growth and promote apoptosis,and emphasize that BSS-MD are promising adjuvants for NSCLC treatment.
文摘Objective: To evaluate the effect of Shashen Maidong Decoction (SSMDD) on gastric motility.Method: Effect of SSMDD on the gastric motility of mice and rats was observed in vivo by administration of SSMDD in various dosages and observation on gastric phenol red excretion rate, gastric emptying rate, frequency and amplitude of contraction of fundic longitudinal muscles, etc. Results: SSMDD could reduce markedly the gastric phenol red excretion rate of mice, antagonize the acceleration of gastric emptying induced by neostigmine, inhibit the frequency and amplitude of contraction of fundic longitudinal muscle, slow down the frequency and decrease the amplitude of gastric peristalsis, and reduce the gastric hypermotility induced by indomethacin significantly. Conclusion: SSMDD has evident inhibition action on motility of experimental animals in vivo, its mechanism might be related with adrenergic nerve and metabolism of prostaglandin E.
